Category Regulatory

Revvity, MDIC, and NIST Launch Somatic Cancer Reference Standards to Ensure Diagnostic Accuracy

Revvity Launches Next-Generation Somatic Cancer Reference Standards in Collaboration with MDIC and NIST Revvity, Inc. today announced the release of its new, highly characterized Mimix™ Geni™ somatic cancer reference standards, developed in collaboration with the Medical Device Innovation Consortium (MDIC)…

Read MoreRevvity, MDIC, and NIST Launch Somatic Cancer Reference Standards to Ensure Diagnostic Accuracy

CrossBridge Bio Named “Best Drug Developer” at 2025 World ADC Awards

CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation dual-payload antibody-drug conjugates (ADCs), announced that it has received the…

Read MoreCrossBridge Bio Named “Best Drug Developer” at 2025 World ADC Awards

Indapta Highlights Clinical Activity of Allogeneic NK Therapy in R/R Multiple Myeloma

Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune disease, has presented…

Read MoreIndapta Highlights Clinical Activity of Allogeneic NK Therapy in R/R Multiple Myeloma

Northwell Study Shows Promising Seizure Reduction for Chronic Epilepsy Patients

Northwell Study Offers Nuanced Hope for Long-Term Seizure Reduction in Chronic, Treatment-Resistant Epilepsy For millions of individuals worldwide, epilepsy remains one of the most challenging chronic neurological disorders to manage. Although many patients achieve seizure control through medication, roughly one-third…

Read MoreNorthwell Study Shows Promising Seizure Reduction for Chronic Epilepsy Patients

Genetix Biotherapeutics to Share U.S. Gene Therapy Patient Experience Data at ASH 2025

Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S. commercial implementation of its landmark gene therapies LYFGENIA™ and ZYNTEGLO™…

Read MoreGenetix Biotherapeutics to Share U.S. Gene Therapy Patient Experience Data at ASH 2025

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement for the development, manufacturing, and commercialization of…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma